Science News from ACC 2019

March 16–18, 2019 | New Orleans, Louisiana

Saturday, March 16


Apple Heart Study

Marco Perez, MD summarizes the results of the Apple Heart Study, which tested whether a smart watch application could effectively detect rhythm abnormalities. Jump to the Apple Heart science.


PARTNER 3 Trial

Martin Leon, MD and Michael Mack, MD provide an overview of the results of PARTNER 3 which were presented at ACC 2019 in New Orleans. Jump to PARTNER 3 science.


Self-Expanding Transcatheter or Surgical AVR in Severe AS

Michael Reardon, MD, breaks down the results of this trial comparing self-expanding transcatheters with surgical AVR in patients with severe aortic stenosis with low risk of mortality. Jump to Dr. Reardon's science.


CODIACS QoL: Depression screening after ACS

Principal investigator Ian M. Kronish, MD, MPH, of Columbia University explains whether screening patients for depression post-ACS had an impact on outcomes. Jump to CODIACS QoL science.

Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias
Mintu Turakhia and Marco Perez | Stanford University, Stanford, CA



PARTNER 3: The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis (P3)
Martin Leon | The PARTNER 3 Trial Investigators, Columbia University Medical Center, New York, NY



Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality
Michael J. Reardon | Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA



PANACHE: A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Sanjiv Jayendra Shah | Northwestern University, Chicago, IL


CODIACS-QoL: Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes
Ian Matthew Kronish | Columbia University Medical Center, New York, NY



Hopeful Heart: Blended Collaborative Care for Heart Failure and Co-Morbid Depression
Bruce Rollman | University of Pittsburgh School of Medicine, Pittsburgh, PA



PIONEER-HF: Results of the Open-Label Extension
Adam DeVore | Duke Clinical Research Institute, Durham, NC



HoT-PE: Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial
Stavros V. Konstantinides and Irene Schmidtmann | HoT-PE Investigators, Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany

Sunday, March 17


2019 CVD Primary Prevention Guideline: A Deep Dive

Donna Arnett, MSPH, PhD and Erin Michos, MD, MHS provide an in-depth look at the 2019 Guideline on the Primary Prevention of Cardiovascular Disease.


2019 CVD Primary Prevention Guideline: Top Take Home Messages

Donna Arnett, MSPH, PhD and Erin Michos, MD discuss their top take home messages for the new 2019 Guideline on the Primary Prevention of Cardiovascular Disease.


AUGUSTUS Trial

Renato Lopes, MD, MHS, PhD, summarizes the results of the AUGUSTUS trial, which compared treatment outcomes for patients with AF and ACS and/or PCI, and also taking a P2Y12 inhibitor. Jump to AUGUSTUS science.

COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation
Federico M. Asch | MedStar Health Research Institute, Hyattsville, MD



Quality of Life After Transcatheter Mitral-Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation
Suzanne Arnold | Saint Luke's Mid America Heart Institute, Kansas City, MO



STS/ACC Transcatheter Valve Therapy Registry (TVT Registry) (TVTR)
Raj R. Makkar | Cedars Sinai Heart Institute, Los Angeles, CA



AUGUSTUS: A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
Renato D. Lopes | Duke Clinical Research Institute, Durham, NC



WRAP-IT: World-wide Randomized Antibiotic Envelope Infection Prevention Trial
Khaldoun G. Tarakji | Cleveland Clinic, Cleveland, OH



POET: Partial Oral Treatment of Left-Sided Infectious Endocarditis Long Term Follow-Up
Henning Bundgaard | The Heart Center, The National University Hospital, Rigshospitalet, Copenahagen, Denmark


MOMENTUM 3: Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ Final Analysis
Mandeep R. Mehra for the MOMENTUM 3 Investigators | Brigham and Women's Hospital Heart and Vascular Center, Boston, MA



CardioMEMS HF System Post Approval Study
David Mark Shavelle | University of Southern California, Los Angeles, CA



REVERSAL: Reversal of the Anti-platelet Effects of Ticagrelor
Deepak L. Bhatt | Brigham and Women's Hospital, Boston, MA



DEFINE PCI: Physiologic Assessment of Coronary Stenosis Following PCI
Allen Jeremias | Cardiovascular Research Foundation, New York, NY



Impact of FFRCT on 1-Year Outcomes in Patients Evaluated: Lessons from the ADVANCE Registry
Manesh R. Patel | Duke University Medical Center, Durham, NC



MRUSMI: Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction
Wilson Mathias | Heart Institute (InCor) - University of Sao Paulo, Sao Paulo, Brazil



GLASSY: GLOBAL LEADERS Adjudication Sub-Study
Marco Valgimigli | GLASSY Investigators, University of Bern, Bern, Switzerland

Monday, March 18


CREOLE Study

Dike Ojji, MBBS, PhD provides an overview of the results of the CREOLE study, which compared three 2-drug therapy combinations to lower BP in sub-Saharan Africans. Jump to CREOLE science.


Alcohol AF Study

Alexandr Voskoboinik, MD provides an overview of the results of ALCOHOL AF, which tracked the effects of alcohol abstinence in moderate drinkers with atrial fibrillation. Jump to Alcohol AF science.

CLEAR Wisdom: Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Anne C. Goldberg | Esperion Therapeutics, Inc., Ann Arbor, MI



CREOLE: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans
Dike Ojji | Creole Study Investigators, University of Abuja, Abuja, Nigeria



INFINITY: Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
William B. White | University of Connecticut School of Medicine, Farmington, CT



Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus Based on Ejection Fraction
Eri T. Kato | TIMI Study Group, Boston, MA



Reduction in Total Ischemic Events with Icosapent Ethyl in REDUCE-IT
Deepak L. Bhatt | for the REDUCE-IT Investigators, Brigham and Women's Hospital, Boston, MA



SAFARI-STEMI: Femoral Versus Radial Access for Primary PCI
Michel R. Le May | University of Ottawa Heart Institute, Ottawa, Canada



Coronary Angiography after Cardiac Arrest
Jorrit Lemkes | Amsterdam University Medical Centre, Amsterdam, The Netherlands



TREAT: Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
Otavio Berwanger | Research Institute - HCor, Sao Paulo, Brazil

STOPDAPT-2: ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
Hirotoshi Watanabe | STOPDAPT-2 investigators, Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto



SMART-CHOICE: Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES
Joo-Yong Hahn | Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea



Alcohol AF: Impact of Alcohol Abstinence in Moderate Drinkers with Atrial Fibrillation: Results from the Alcohol-AF Randomized Controlled Trial
Aleksandr Voskoboinik | Baker Heart & Diabetes Institute, Melbourne, Australia



Impact of ADCY9 on Response to Anacetrapib Among 20,000 Participants in the HPS3/TIMI55-REVEAL Trial
Jemma Caroline Hopewell, HPS3/TIMI55 REVEAL Collaborative Group, University of Oxford, Oxford, United Kingdom



ODYSSEY OUTCOMES: Lipoprotein(a) Lowering by Alirocumab Contributes to Total Events Reduction Independent of Low-Density Lipoprotein Cholesterol in the ODYSSEY OUTCOMES Trial
Vera Bittner | University of Alabama at Birmingham, Birmingham, AL



Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE - TIMI 58
Marc P. Bonaca | Brigham and Women'S Hospital, Boston, MA



Acute Aortic Dissection: Lessons Learned from 9000 Patients
Kim Eagle | University of Michigan, Ann Arbor, MI